A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.

[1]  M. Serrano,et al.  p19ARF links the tumour suppressor p53 to Ras , 1998, Nature.

[2]  M. Barbacid,et al.  Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in β-islet cell hyperplasia , 1999, Nature Genetics.

[3]  P. Pandolfi,et al.  Targeted Disruption of CDK4 Delays Cell Cycle Entry with Enhanced p27Kip1 Activity , 1999, Molecular and Cellular Biology.

[4]  T. Hupp,et al.  Posttranslational Modifications of p53 in Replicative Senescence Overlapping but Distinct from Those Induced by DNA Damage , 2000, Molecular and Cellular Biology.

[5]  Ming You,et al.  Wildtype Kras2 can inhibit lung carcinogenesis in mice , 2001, Nature Genetics.

[6]  J. Harper,et al.  A premature-termination mutation in the Mus musculus cyclin-dependent kinase 3 gene. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[7]  C. Conti,et al.  Cdk4 deficiency inhibits skin tumor development but does not affect normal keratinocyte proliferation. , 2002, The American journal of pathology.

[8]  Marshall W. Anderson,et al.  LOH of chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer , 2003, Oncogene.

[9]  Pierre Dubus,et al.  Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice , 2003, Nature Genetics.

[10]  Manuel Serrano,et al.  Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. , 2003, Cancer cell.

[11]  J. Minna,et al.  Loss of heterozygosity of chromosome 12p does not correlate with KRAS mutation in non‐small cell lung cancer , 2003, International journal of cancer.

[12]  C. Conti,et al.  Lack of Cyclin-Dependent Kinase 4 Inhibits c-myc Tumorigenic Activities in Epithelial Tissues , 2004, Molecular and Cellular Biology.

[13]  Pierre Dubus,et al.  Mammalian Cells Cycle without the D-Type Cyclin-Dependent Kinases Cdk4 and Cdk6 , 2004, Cell.

[14]  R. DePinho,et al.  Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. , 2004, Cancer cell.

[15]  N. Pryer,et al.  Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. , 2004, Molecular cancer therapeutics.

[16]  M. Barbacid,et al.  Tumour biology: Senescence in premalignant tumours , 2005, Nature.

[17]  T. Jacks,et al.  The differential effects of mutant p53 alleles on advanced murine lung cancer. , 2005, Cancer research.

[18]  Pierre Dubus,et al.  Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1). , 2005, Cancer cell.

[19]  Yan Geng,et al.  Requirement for CDK4 kinase function in breast cancer. , 2006, Cancer cell.

[20]  Tiansen Li,et al.  Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. , 2006, Cancer cell.

[21]  Dimitris Kletsas,et al.  Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints , 2006, Nature.

[22]  Aaron Bensimon,et al.  Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication , 2006, Nature.

[23]  Frédérick A. Mallette,et al.  The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. , 2007, Genes & development.

[24]  Pierre Dubus,et al.  Cdk1 is sufficient to drive the mammalian cell cycle , 2007, Nature.

[25]  M. Barbacid,et al.  Mice thrive without Cdk4 and Cdk2 , 2007, Molecular oncology.

[26]  C. Bassing,et al.  Genotoxic Stress-Induced Cyclin D1 Phosphorylation and Proteolysis Are Required for Genomic Stability , 2008, Molecular and Cellular Biology.

[27]  D. Peeper,et al.  Cellular senescence in vivo: a barrier to tumorigenesis. , 2008, Current opinion in cell biology.

[28]  Allan Balmain,et al.  Kras regulatory elements and exon 4A determine mutation specificity in lung cancer , 2008, Nature Genetics.

[29]  James R Bischoff,et al.  CDK inhibitors in cancer therapy: what is next? , 2008, Trends in pharmacological sciences.

[30]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[31]  Jun Yokota,et al.  A gene‐alteration profile of human lung cancer cell lines , 2009, Human mutation.

[32]  Sridhar Ramaswamy,et al.  Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells , 2009, Cell.

[33]  M. Barbacid,et al.  Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.

[34]  A. Giordano,et al.  Cell cycle kinases as therapeutic targets for cancer , 2009, Nature Reviews Drug Discovery.

[35]  M. Barbacid,et al.  Cdk2 suppresses cellular senescence induced by the c-myc oncogene , 2010, Nature Cell Biology.